Responses
Clinical and epidemiological research
Extended report
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
Compose a Response to This Article
Other responses
No responses have been published for this article.